新型流感疫苗M2SR在具有既往免疫的雪貂中抵御漂移H1N1和H3N2流感病毒攻击
研究在无既往免疫和具有既往免疫的雪貂中评估新型M2SR流感疫苗对漂移流感病毒的保护效果。无既往免疫雪貂中M2SR与对照疫苗FluMist保护作用相似,而在两种既往免疫模型中M2SR提供的保护优于FluMist。结果提示单次复制鼻内M2SR疫苗在无既往免疫和具有既往免疫的雪貂中均能有效抵御漂移甲型流感病毒。
要点
- 无既往免疫雪貂中M2SR对漂移攻击病毒的保护与FluMist相似。
- 既往免疫雪貂中M2SR对漂移H3N2攻击的保护优于单价FluMist。
- 既往同源免疫对FluMist的影响大于对M2SR的影响。
核心结论
- 单次复制鼻内M2SR疫苗不仅在无既往免疫雪貂中、也在具有既往免疫的雪貂中提供对漂移甲型流感病毒的有效保护,与FluMist病毒相反。
研究设计与样本
- 在无既往免疫雪貂和具有既往免疫的雪貂中评估M2SR流感疫苗抵御漂移流感病毒的能力。
- 第一模型:雪貂先感染甲型H1N1pdm和乙型流感病毒,对H1N1pdm和乙型流感血清阳性但对H3N2血清阴性,随后接种H3N2 M2SR或单价H3N2 FluMist病毒(A/Brisbane/10/2007,clade 1),6周后用漂移H3N2病毒(clade 3C.2a)攻击。
- 第二模型:雪貂先感染H1N1pdm病毒,90天后接种H1N1pdm M2SR或单价FluMist疫苗,6周后用大流行前季节性H1N1病毒A/Brisbane/59/2007(Bris59)攻击。
主要发现
- 第一模型中,既往感染雪貂对Brisbane/10/2007的抗体滴度M2SR接种组高于FluMist接种组,而无既往免疫雪貂中观察到相反结果。
- 第一模型中,漂移H3N2病毒攻击后M2SR提供的保护优于单价FluMist疫苗。
- 第二模型中,接种后检测到针对Bris59 HA的交叉反应血清IgG抗体,但抗Bris59血凝抑制抗体仅在攻击后检测到。
- 第二模型中,M2SR对Bris59攻击提供的保护优于FluMist,提示同源既往免疫对FluMist病毒的影响大于对M2SR的影响。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Current influenza vaccines do not provide effective protection against heterologous influenza viruses. The ability of the novel M2SR influenza vaccine to protect against drifted influenza viruses was evaluated in naïve ferrets and in ferrets with pre-existing immunity to influenza. In naïve ferrets, M2SR provided similar protection against drifted challenge viruses as the comparator vaccine, FluMist®. However, in ferrets with pre-existing immunity, M2SR provided superior protection than FluMist in two model systems. In the first model, ferrets were infected with influenza A H1N1pdm and influenza B viruses to mimic the diverse influenza exposure in humans. The pre-infected ferrets, seropositive to H1N1pdm and influenza B but seronegative to H3N2, were then vaccinated with H3N2 M2SR or monovalent H3N2 FluMist virus (A/Brisbane/10/2007, clade 1) and challenged 6 weeks later with a drifted H3N2 virus (clade 3C.2a). Antibody titers to Brisbane/10/2007 were higher in M2SR vaccinated ferrets than in FluMist vaccinated ferrets in the pre-infected ferrets whereas the opposite was observed in naïve ferrets. After challenge with drifted H3N2 virus, M2SR provided superior protection than FluMist monovalent vaccine. In the second model, the impact of homologous pre-existing immunity upon vaccine-induced protection was evaluated. Ferrets, pre-infected with H1N1pdm virus, were vaccinated 90 days later with H1N1pdm M2SR or FluMist monovalent vaccine and challenged 6 weeks later with a pre-pandemic seasonal H1N1 virus, A/Brisbane/59/2007 (Bris59). While cross-reactive serum IgG antibodies against the Bris59 HA were detected after vaccination, anti-Bris59 hemagglutination inhibition antibodies were only detected post-challenge. M2SR provided better protection against Bris59 challenge than FluMist suggesting that homologous pre-existing immunity affected FluMist virus to a greater degree than M2SR. These results suggest that the single replication intranasal M2SR vaccine provides effective protection against drifted influenza A viruses not only in naïve ferrets but also in those with pre-existing immunity in contrast to FluMist viruses.
引用
- Hatta Y, Boltz D, Sarawar S, et al. Novel influenza vaccine M2SR protects against drifted H1N1 and H3N2 influenza virus challenge in ferrets with pre-existing immunity. Vaccine. 2018. PMID: 30007825. doi:10.1016/j.vaccine.2018.06.053
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。